Replies to post #277807 on Anavex Life Sciences Corp (AVXL)

[Steady_T]

OMG Georgejj You found another DOT.

[jtsmgoblue]

George...

Great find. Anavex and Northwestern are both attendees. CM giving back to his alma mater!

Day 1
2:50 pm Cross-Learnings from Mechanisms of Action Underlying Protein Conformational Disorders

Christopher Missling
President & CEO, Anavex Life Sciences
Synopsis

How to evaluate the safety and tolerability of novel protein misfolding therapeutics as assessed through clinical development
How can the commonalities in underlying molecular pathology be used to inform the development of new treatment options for protein-misfolding diseases?
How can you leverage a clinical developmental strategy to address a range of diseases caused by protein misfolding for which no approved disease-modifying treatments currently exist?

Day 2
2:00 pm Panel Discussion: Conducting a Strategic Analysis of Protein Misfolding Therapeutics

Robert Scannevin
Head of Research , Yumanity
Neil Cashman
CSO & Co-Founder, ProMIS Neurosciences
Gergely Tóth
Founder & CEO, CantaBio Pharmaceuticals
Christopher Missling
President & CEO, Anavex Life Sciences
Synopsis

• What are the strengths of companies active in developing protein misfolding therapeutics?
• What is a bird’s eye view of the space in terms of how money has flowed in/out?
• What do companies in this space need to change or improve to accelerate their scientific progress?
• What is the market opportunity and unmet need that makes protein misfolding therapeutics an attractive but high hanging fruit in terms of therapeutic potential?


So many games still being played 930-400. It doesn’t matter. The game is over.